Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
Phase 2
Completed
- Conditions
- COVID-19, SARS CoV 2 Infection
- Interventions
- Biological: Pfizer/BNT vaccine (30 mcg)Biological: ChulaCov19 BNA159 vaccine (50 mcg)Biological: COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Technovalia, Pty Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT05605470
- Locations
- 🇦🇺
Paratus research Canberra Clinic, Bruce, Australian Capital Territory, Australia
🇦🇺Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
News
No news found